RU School Of Osteopathic Medicine

RU School Of Osteopathic Medicine, a state-controlled institution of higher learning based in Stratford, New Jersey and a subsidiary of Rowan University, generates the majority of its federal revenue through tuition and medical education services delivered to the Department of the Navy's Bureau of Medicine and Surgery under a single-award Basic Ordering Agreement (BOA) running through September 2034, with supplemental research grant funding from the National Institutes of Health, SAMHSA, and other federal agencies. The institution operates as a prime recipient across 114 federal awards (93% of total) spanning both contracts and grants, with 31 task orders and delivery orders under the Navy BOA anchoring over $3.5 million in combined potential value.

Navy medical education dominates the customer portfolio. The Bureau of Medicine and Surgery accounts for 52% of awards by count (34 awards, $3.8 million potential value) through firm fixed-price delivery orders for tuition and fees supporting Navy medical personnel training. Recent Navy contracts include a $131,692 delivery order awarded December 11, 2025, a $146,791 delivery order from July 1, 2025, and a $243,244 delivery order from December 2, 2024, all supporting training of military healthcare professionals with performance in Stratford, New Jersey. Individual task orders under the Navy BOA range from approximately $24,000 to $303,000 and carry no set-aside designation. Beyond the Navy contract footprint, grant work distributed across five federal grant agencies reflects the institution's research infrastructure. The National Institute on Aging, National Institute of General Medical Sciences, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Neurological Disorders and Stroke, National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, SAMHSA Center for Substance Abuse Treatment, SAMHSA Center for Mental Health Services, Bureau of Health Professionals, Bureau of Justice Assistance, Department of Veterans Affairs, and Defense Health Agency together account for approximately 30 grants spanning biomedical research in neuroscience, addiction medicine, cancer biology, trauma and mental health, and medical workforce development.

Representative grant awards illustrate the research capability: a $2.29 million National Institute on Deafness and Other Communication Disorders project grant (CFDA 93.173) awarded August 6, 2025, investigating hedgehog signaling in postnatal tongue morphogenesis through July 31, 2029; a $616,000 National Institute of Dental and Craniofacial Research project grant (CFDA 93.121) awarded August 1, 2025, evaluating hedgehog pathway inhibition as therapeutic strategy for oral squamous cell carcinoma through July 31, 2029; and a $423,708 National Institute on Drug Abuse project grant (CFDA 93.279) awarded September 30, 2024, investigating fentanyl-xylazine mixtures' cardiorespiratory effects through September 29, 2026. Medical workforce development grants include a $1.1 million Bureau of Health Professionals pathways-to-primary-care program (awarded September 30, 2024) and a $750,000 Veterans Health Administration suicide prevention grant (awarded October 1, 2023, extended). The institution also serves as sub-recipient on grants from Johns Hopkins University, UCLA, Northeast Ohio Medical University, Tulane University, and other research institutions, performing specialized analyses, data processing, and investigative work in virology, neuropsychology, and behavioral health.

Activity has remained relatively stable, averaging 10 awards per year from 2021 through 2024, with nine awards in 2025. The Navy BOA provides institutional stability despite the modest near-term recompete exposure: only 17 awards (combined potential value $132,000) reach ultimate completion within the next twenty-four months. The institution's federal footprint is concentrated in medical education delivery and basic biomedical research with particular emphasis on neuroscience, addiction medicine, and mental health across the NIH portfolio and SAMHSA grant programs. No procurement vehicles, GWACs, or government-wide schedules are held; all federal work flows through direct agency awards or sub-awards from primary research institutions.